Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioGaia AB ( ($SE:BIOG.B) ) has provided an update.
BioGaia said its preliminary results for the fourth quarter of 2025 will exceed market expectations, with sales estimated at SEK 441 million, up 21% year-on-year (32% excluding currency effects), partly boosted by around SEK 35 million in quarterly order variations. Operating profit is expected to rise to SEK 121 million from SEK 103 million, corresponding to an operating margin of 27%, underlining solid profitability ahead of the full interim report due on 12 February 2026, and reinforcing the company’s position in the global probiotics market.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK125.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia is a Swedish probiotic company that has been a leader in microbiome research for more than 35 years, developing, manufacturing, marketing and selling probiotic products targeting gut, immune and oral health. Its products are distributed via partners and its own channels in over 100 markets worldwide, and its class B shares are listed on the Mid Cap segment of Nasdaq Stockholm.
Average Trading Volume: 292,069
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK11.2B
See more insights into BIOG.B stock on TipRanks’ Stock Analysis page.